Guoying Tai
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Pharmacological Effects and Toxicity Studies, HIV/AIDS drug development and treatment, Cancer therapeutics and mechanisms
Most-Cited Works
- → Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective(2020)120 cited
- → In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose(2005)63 cited
- → Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development(2013)40 cited
- → Localization of the C‐terminus of rat glutathione S‐transferase A1‐1: Crystal structure of mutants W21F and W21F/F220Y(2000)28 cited
- → CYP2C9 Amino Acid Residues Influencing Phenytoin Turnover and Metabolite Regio- and Stereochemistry(2009)23 cited
- → Pharmacokinetics of Gepotidacin in Renal Impairment(2020)16 cited
- → CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians(2003)15 cited
- → Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development(2022)14 cited
- → Re-engineering of CYP2C9 to Probe Acid-Base Substrate Selectivity(2008)14 cited
- → Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague(2021)11 cited